These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 23247492)

  • 21. Lack of anti-drug antibodies in patients with psoriasis well-controlled on long-term treatment with tumour necrosis factor inhibitors.
    Meyer MW; Zachariae C; Bendtzen K; Skov L
    Acta Derm Venereol; 2012 Jul; 92(4):362-4. PubMed ID: 22864558
    [No Abstract]   [Full Text] [Related]  

  • 22. Safety and efficacy study on etanercept in patients with plaque psoriasis.
    Costanzo A; Mazzotta A; Papoutsaki M; Nisticò S; Chimenti S
    Br J Dermatol; 2005 Jan; 152(1):187-9. PubMed ID: 15656833
    [No Abstract]   [Full Text] [Related]  

  • 23. Mean platelet volume variation after biologic therapy in psoriasis and psoriatic arthritis.
    Capo A; Di Nicola M; Auriemma M; Piaserico S; Cuccurullo C; Santilli F; Davi G; Amerio P
    Eur J Dermatol; 2014; 24(1):133-5. PubMed ID: 24589526
    [No Abstract]   [Full Text] [Related]  

  • 24. Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients.
    Prignano F; Ricceri F; Pescitelli L; Zanieri F; Lotti T
    Br J Dermatol; 2011 Mar; 164(3):645-7. PubMed ID: 21375517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor necrosis factor inhibitors in the treatment of chronic inflammatory diseases. A review of immunogenicity and potential implications.
    Flood J
    Manag Care; 2009 Apr; 18(4 Suppl 3):1-5. PubMed ID: 19562866
    [No Abstract]   [Full Text] [Related]  

  • 26. [Psoriasis and psoriatic rheumatism: effectiveness of etanercept for cutaneous and joint lesions].
    Paul C; Solignac M
    Ann Dermatol Venereol; 2010 Apr; 137(4 Suppl):13-5. PubMed ID: 20510165
    [No Abstract]   [Full Text] [Related]  

  • 27. ["MGUS": a potentially under diagnosed event during anti-TNF-α treatment of psoriasis?].
    Schmutz JL; Trechot P
    Ann Dermatol Venereol; 2013 Feb; 140(2):157-8. PubMed ID: 23395504
    [No Abstract]   [Full Text] [Related]  

  • 28. Anti-TNF-alpha therapy in childhood pustular psoriasis.
    Pereira TM; Vieira AP; Fernandes JC; Antunes H; Basto AS
    Dermatology; 2006; 213(4):350-2. PubMed ID: 17135745
    [No Abstract]   [Full Text] [Related]  

  • 29. Etanercept at different dosages in the treatment of generalized pustular psoriasis: a case series.
    Esposito M; Mazzotta A; Casciello C; Chimenti S
    Dermatology; 2008; 216(4):355-60. PubMed ID: 18285687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autoantibodies in psoriatic patients treated with anti-TNF-α therapy.
    Bardazzi F; Odorici G; Virdi A; Antonucci VA; Tengattini V; Patrizi A; Balestri R
    J Dtsch Dermatol Ges; 2014 May; 12(5):401-6. PubMed ID: 24797746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Tolerance of biological agents in children].
    Bader-Meunier B
    Arch Pediatr; 2010 Jun; 17(6):962-3. PubMed ID: 20654981
    [No Abstract]   [Full Text] [Related]  

  • 32. Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.
    Girolomoni G; Altomare G; Ayala F; Berardesca E; Calzavara-Pinton P; Chimenti S; Peserico A; Puglisi Guerra A; Vena GA
    Immunopharmacol Immunotoxicol; 2012 Aug; 34(4):548-60. PubMed ID: 22296031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor necrosis factor inhibitors for rheumatoid arthritis.
    Scott DL; Kingsley GH
    N Engl J Med; 2006 Aug; 355(7):704-12. PubMed ID: 16914706
    [No Abstract]   [Full Text] [Related]  

  • 34. Severe generalized exanthema due to etanercept given for severe plaque psoriasis.
    Gonzalo-Garijo MA; Pérez-Calderón R; de Argila Fernández-Durán D
    Ann Allergy Asthma Immunol; 2008 Jun; 100(6):621-2. PubMed ID: 18592833
    [No Abstract]   [Full Text] [Related]  

  • 35. Ixekizumab for psoriasis.
    Tsuda K; Tanimoto T; Takenouchi S; Sakaue S; Komatsu T
    Lancet; 2016 Jan; 387(10015):225-6. PubMed ID: 26842296
    [No Abstract]   [Full Text] [Related]  

  • 36. Sustained efficacy and safety of adalimumab in psoriasis treatment: a retrospective study of 49 patients with and without a history of TNF-alpha antagonist treatment.
    Van L; Modi SV; Yang DJ; Hsu S
    Arch Dermatol; 2008 Jun; 144(6):804-6. PubMed ID: 18559778
    [No Abstract]   [Full Text] [Related]  

  • 37. Pityriasis rubra pilaris types 1 and 2: different responses to treatment with TNF-alpha antagonists.
    Vujic I; Richter L; Bartsch K; Monshi B; Rappersberger K
    Eur J Dermatol; 2013; 23(6):895-6. PubMed ID: 24192269
    [No Abstract]   [Full Text] [Related]  

  • 38. Pancolitis during etanercept treatment of rheumatoid arthritis relapsing on the administration of further two TNF-alpha inhibitors.
    Actis GC; Lagget M; Pellicano R; Rosina F
    Int J Colorectal Dis; 2012 Apr; 27(4):547-8. PubMed ID: 21656142
    [No Abstract]   [Full Text] [Related]  

  • 39. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis.
    Langley RG; Strober BE; Gu Y; Rozzo SJ; Okun MM
    Br J Dermatol; 2010 Jun; 162(6):1349-58. PubMed ID: 20394634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment.
    Nordgaard-Lassen I; Dahlerup JF; Belard E; Gerstoft J; Kjeldsen J; Kragballe K; Ravn P; Sørensen IJ; Theede K; Tjellesen L;
    Dan Med J; 2012 Jul; 59(7):C4480. PubMed ID: 22759856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.